Represents the additional term of extension of the collaborative agreement.

No definition available.

Name:	imgn_CollaborativeArrangementAdditionalExtensionTerm
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the initial period of the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementAgreementTerm
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the estimated utilization period after commercialization of the product, which is used to allocate fees to the deliverables in the contract.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementAllocationOfDeliverablesAssumptionsUtilizationPeriod
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the term of extension of the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementExtensionTerm
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the estimated term of licenses under the collaborative arrangements.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementLicensesEstimatedTerm
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of potential payments that could be received under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementMilestonePaymentsPotential
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the number of development and commercialization licenses.

+ References

No definition available.

+ Details

Name:	imgn_NumberOfDevelopmentAndCommercializationLicenses
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of single-target licenses the company has right to use.

+ References

No definition available.

+ Details

Name:	imgn_NumberOfSingleTargetLicenses
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the payments to be made for extension of the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_PaymentsForCollaboratorsContractExtension
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents information pertaining to value of collaborators licenses after extension.

+ References

No definition available.

+ Details

Name:	imgn_ValueOfCollaboratorsLicensesAfterExtension
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueInputsDiscountRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=imgn_TakedaOncologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_FutureTechnologicalImprovementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_ResearchServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_RightToTestMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_OptionToExpandAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_DevelopmentAndCommercializationLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_DevelopmentPhaseAxis=imgn_PhaseIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_OptionToExpandAgreementForOneAdditionalYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Agreements (Details 9)	1 Months Ended	3 Months Ended								12 Months Ended
Agreements (Details 9)	Mar. 31, 2015 USD ($) item	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Sep. 30, 2013 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2013 USD ($)
Collaborative Agreements disclosures
Costs related to the research and development services		$ 30,437,000	$ 25,666,000	$ 27,647,000	$ 28,018,000	$ 25,787,000	$ 38,280,000	$ 20,862,000	$ 22,029,000	$ 111,768,000	$ 106,958,000	$ 87,073,000
Takeda
Collaborative Agreements disclosures
Payments received under collaboration agreement	$ 31,400,000
Costs related to the research and development services										$ 113,000
Takeda \| Future Technological Improvements
Collaborative Agreements disclosures
Payments received under collaboration agreement	2,100,000
Takeda \| Research Services
Collaborative Agreements disclosures
Payments received under collaboration agreement	$ 3,400,000
Takeda \| Right-to-test agreement
Collaborative Agreements disclosures
Number of single-target licenses \| item	2
Term of agreement	3 years
Term of extension of the agreement	1 year
Payments to be made for extension of agreement	$ 4,000,000
Payments received under collaboration agreement	20,000,000
Takeda \| Right-to-test agreement \| Maximum
Collaborative Agreements disclosures
Potential milestone payments	210,000,000		210,000,000
Takeda \| Right-to-test agreement \| Development milestones \| Maximum
Collaborative Agreements disclosures
Potential milestone payments	30,000,000		30,000,000
Takeda \| Right-to-test agreement \| Regulatory milestones \| Maximum
Collaborative Agreements disclosures
Potential milestone payments	85,000,000		85,000,000
Takeda \| Right-to-test agreement \| Sales milestones \| Maximum
Collaborative Agreements disclosures
Potential milestone payments	95,000,000		95,000,000
Takeda \| Right-to-test agreement \| Option To Expand Agreement
Collaborative Agreements disclosures
Payments to be made for extension of agreement	8,000,000
Takeda \| Development and Commercialization License
Collaborative Agreements disclosures
Payments received under collaboration agreement	$ 25,900,000
Discount rate (as a percent)	13.00%
Estimated utilization period after commercialization	10 years
Estimated term of development and commercialization license	25 years
Number of development and commercialization licenses \| item	3
Takeda \| Development and Commercialization License \| Phase I clinical trial
Collaborative Agreements disclosures
Potential milestone payments	$ 5,000,000		5,000,000
Takeda \| Development and Commercialization License \| Option To Expand Agreement
Collaborative Agreements disclosures
Value of collaborators licenses after extension	$ 8,000,000		$ 8,000,000
Additional term of extension of the agreement	2 years
Number of development and commercialization licenses \| item	2
Takeda \| Development and Commercialization License \| Option to expand agreement for one additional year
Collaborative Agreements disclosures
Term of extension of the agreement	1 year
Payments to be made for extension of agreement	$ 4,000,000